01 Growing Adoption of Advanced Lipid and Lipoprotein Biomarker Testing Cholesterol testing is moving beyond conventional measurements of total cholesterol, LDL-C, HDL-C, and triglycerides toward more detailed lipid and lipoprotein assessment. Advanced biomarkers such as Lipoprotein(a) [Lp(a)] and Apolipoprotein B (ApoB) can provide additional information about cardiovascular risk that may not be fully captured through a standard lipid profile. This transition is encouraging diagnostic laboratories and cardiovascular care providers to broaden testing portfolios and incorporate additional biomarkers into individualized risk assessment. In March 2026, the American College of Cardiology and American Heart Association released updated dyslipidemia guidelines recommending that Lp(a) be measured at least once in adulthood. The guidelines also support ApoB measurement in selected patients, including those with elevated triglycerides, diabetes, or residual cardiovascular risk. The increasing clinical recognition of additional lipid biomarkers is shifting cholesterol testing toward more comprehensive cardiovascular risk profiling and supporting the adoption of tests that complement conventional cholesterol measurements.
02 Increasing Use of Lipidomics for Detailed Cardiovascular Risk Assessment Lipidomics is emerging as an advanced approach for examining numerous lipid species rather than relying exclusively on conventional cholesterol measurements. Mass-spectrometry-based techniques can characterize ceramides, phospholipids, lysophospholipids, and other lipid molecules associated with cardiovascular disease. This approach provides researchers with a more detailed understanding of lipid metabolism and may help identify biomarkers associated with disease development and progression. In March 2025, researchers published a comprehensive evaluation of lipidomics in cardiovascular disease, highlighting advances in liquid chromatography-mass spectrometry and other lipidomic techniques for identifying lipid biomarkers associated with myocardial infarction, heart failure, stroke, and other cardiovascular conditions. As lipidomics technologies become more standardized and clinically validated, they could complement conventional cholesterol testing and support more precise cardiovascular risk assessment.
01 High Burden of Elevated Cholesterol Increases Routine Testing Requirements The high prevalence of abnormal cholesterol levels is strengthening cholesterol test market demand because elevated LDL cholesterol is an established risk factor for atherosclerotic cardiovascular disease. Excess LDL-C can contribute to plaque accumulation in arteries, increasing the long-term risk of heart attack and stroke. Since high cholesterol generally produces no obvious symptoms, laboratory testing remains important for identifying individuals requiring preventive intervention and ongoing lipid management.The continuing burden of elevated cholesterol is supporting routine testing across primary care practices, hospitals, diagnostic laboratories, preventive healthcare programs, and cardiovascular clinics.
01 Cost and Infrastructure Requirements of Advanced Lipid Testing Advanced cholesterol and lipid assessment can require specialized analyzers, mass spectrometry platforms, reagents, skilled laboratory personnel, and sophisticated data-processing capabilities. These requirements make advanced lipidomic and specialized biomarker testing more complex and expensive than conventional lipid panels available through routine clinical chemistry laboratories.Such infrastructure requirements can restrict the cholesterol test market size, particularly across smaller laboratories, community healthcare facilities, and developing healthcare systems where sophisticated diagnostic technologies are less accessible.Reducing analytical complexity, improving assay standardization, and lowering testing costs will be important for extending advanced lipid assessment beyond specialized laboratories and cardiovascular centers.
01 Expansion of Lp(a) and ApoB Testing Creates New Diagnostic Opportunities Increasing recognition of cardiovascular risk beyond conventional LDL-C measurements is creating opportunities for diagnostic companies and laboratories offering specialized lipid assays. Lp(a) is largely genetically determined, while ApoB provides information about atherogenic lipoprotein particles. Companies expanding access to standardized Lp(a), ApoB, and related assays have opportunities to strengthen their cholesterol test market share as cardiovascular prevention becomes increasingly personalized.
June 2026 Roche Diagnostics launched an upgraded lipid testing solution for clinical laboratories, enhancing automation and accuracy for cholesterol and cardiovascular risk assessment.
April 2026 Abbott expanded its point-of-care diagnostics portfolio with an enhanced cholesterol testing solution designed to provide faster lipid profile analysis in healthcare settings.
December 2025 Siemens Healthineers introduced an advanced clinical chemistry analyzer with improved lipid profile testing capabilities, supporting high-throughput cholesterol diagnostics.
September 2025 Beckman Coulter Diagnostics received regulatory approval for an expanded lipid testing assay, strengthening its cardiovascular diagnostics portfolio for clinical laboratories.